{
  "id": 16542067,
  "title": "Celltrion Expands U.S. Market Access for Omlyclo and Aptozma",
  "url": "https://urgent.news/2026/10/26/celltrion-expands-u-s-market-access-for-omlyclo-and-aptozma",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-26T01:24:51.000Z",
  "source": {
    "name": "Korea IT Times",
    "slug": "korea-it-times",
    "url": "https://www.koreaittimes.com/news/articleView.html?idxno=158510"
  },
  "original_language": "en",
  "account": null,
  "summary": "Celltrion, a South Korean biopharmaceutical company, has expanded its U.S. market access for two newer biosimilar products, Omlyclo and Aptozma, by securing exclusive supply agreements. These agreements are expected to strengthen access to major healthcare networks, insurance coverage, and retail pharmacy channels. The deals mark Celltrion's strategy to leverage relationships with insurers, healthcare providers, and pharmaceutical distributors to increase prescription volumes and sales of its newer, higher-margin products.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}